Stanford Gets Grant for Lymphoma Vaccine Research

Stanford University researchers won a $6.25 million grant from the Leukemia & Lymphoma Society today.



The money will be spent to create a special research center for interdisciplinary work on a possible lymphoma vaccine. Researchers on the project come from the university's departments of medicine, oncology, molecular pharmacology, health research and policy, chemical engineering and from the Stanford Genome Center. Ronald Levy, M.D. (right), a Stanford medical professor and chief of the university's oncology division, will oversee the program. He developed the lymphoma drug Rituxan for Genentech Inc.



Researchers in the program will try to create a vaccine that is tailored to each patient's specific lymphoma. Such a vaccine would attack a patient's cancer cells without hurting the immune system the way traditional chemotherapy does.

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap